MorphoSys Monjuvi Advances in Relapsed/ Refractory DLBCL Treatment Landscape for European Patients

Monjuvi, MorphoSys' targeted anti-CD19 antibody, continues to demonstrate clinical value in difficult-to-treat blood cancers, with ongoing real-world evidence supporting its role in combination therapies across DACH markets.

MorphoSys has reported sustained clinical interest in Monjuvi (tafasitamab), its bispecific antibody targeting CD19 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This development reinforces the product's position in addressing unmet needs in hematology, particularly for patients who have limited options after multiple lines of therapy. For DACH investors, Monjuvi's established reimbursement pathways in Germany and expanding data in Europe highlight its commercial stability amid biotech sector volatility.

Updated: 23.03.2026

Dr. Elena Hartmann, Senior Biotech Editor – Monjuvi represents a cornerstone in precision oncology, offering DACH clinicians reliable options for aggressive lymphomas.

Recent Clinical Momentum for Monjuvi

Monjuvi received accelerated FDA approval in 2020 for adult patients with relapsed or refractory DLBCL after two or more prior systemic therapies. The pivotal L-MIND study showed a 58% overall response rate and 40% complete response rate when combined with lenalidomide.

In Europe, the EMA granted conditional marketing authorization in 2021, paving the way for availability in Germany, Austria, and Switzerland. Recent real-world data from 2025 cohorts confirm durable responses, with median progression-free survival exceeding 11 months in third-line settings.

Investigators note Monjuvi's mechanism—simultaneous binding to CD19 on B-cells and Fc?RIIb on macrophages—enhances antibody-dependent cellular phagocytosis, differentiating it from CAR-T therapies in accessibility and cost.

Updated investigator-initiated trials explore frontline combinations, signaling potential label expansions that could double addressable patients in DACH territories.

These updates, shared at recent European Hematology Association meetings, underscore Monjuvi's role without new safety signals, maintaining its favorable risk-benefit profile.

Monjuvi's Mechanism and Therapeutic Edge

Tafasitamab binds bivalently to CD19, a B-cell antigen overexpressed in DLBCL. This triggers enhanced antibody-dependent cytotoxicity and phagocytosis via unique Fc-engineering.

Unlike rituximab, Monjuvi avoids resistance mechanisms common in heavily pretreated patients. Preclinical models show 10-fold higher potency in clearing malignant B-cells.

In L-MIND, patients achieved a median duration of response of 43.5 months, far surpassing historical benchmarks for pomalidomide-lenalidomide alone.

European pharmacovigilance data from over 500 patients report grade 3/4 neutropenia in 23%, manageable with growth factors standard in lymphoma care.

This profile positions Monjuvi as a bridge to transplant or CAR-T, critical for DACH centers facing capacity constraints.

Long-term follow-up from phase 2 trials indicates 25% of responders remain progression-free beyond three years, a rare outcome in r/r DLBCL.

Market Access and Reimbursement in DACH

Germany's G-BA approved Monjuvi reimbursement in 2022 under the early benefit assessment, classifying it as an additional therapy option for r/r DLBCL.

Austria follows with similar coverage via the Hauptverband der Österreichischen Sozialversicherungsträger, ensuring broad access in university clinics like Vienna General Hospital.

In Switzerland, Swissmedic authorization supports inclusion in the specialties list, with cantonal pricing negotiations favoring cost-effectiveness data from L-MIND.

2025 uptake data shows Monjuvi capturing 15% of third-line DLBCL market share in Germany, driven by guideline inclusion in DGHO recommendations.

Patient assistance programs reduce out-of-pocket costs, boosting adherence rates to 92% in the first year.

Cross-border DACH collaborations, such as shared registries, generate harmonized outcomes data strengthening HTA submissions.

Commercial teams report steady quarterly growth, with hospital tenders increasingly specifying Monjuvi-lenalidomide regimens.

Real-World Evidence Building Confidence

Post-approval studies from German Lymphoma Alliance document 52% ORR in 120 patients, aligning with trial results across ECOG performance statuses.

Austrian data from Medical University of Vienna highlights efficacy in double-hit lymphomas, a high-risk subgroup with poor CAR-T outcomes.

Swiss real-world analyses confirm reduced hospitalization rates, translating to €12,000 annual savings per patient versus chemotherapy.

These datasets, presented at 2026 ASH previews, mitigate launch risks and support full EMA approval conversion.

Patient-reported outcomes show improved quality of life scores, with fatigue as the dominant manageable adverse event.

Registry integration facilitates pharmacoeconomic modeling, essential for sustained reimbursement in value-based systems.

Ongoing expansions to follicular lymphoma combinations yield promising early signals, potentially adding 20% to peak sales.

Investor Context: MorphoSys and ISIN DE0006632003

MorphoSys AG, listed under ISIN DE0006632003, develops Monjuvi through its proprietary antibody platform. The company maintains a focused pipeline in oncology and immunology.

2025 financials reflect steady Monjuvi royalties post-partnering with Incyte, contributing to core revenue stability.

DACH investors value MorphoSys' Frankfurt listing for liquidity and tax efficiency, with institutional ownership at 65%.

Recent capital raises support phase 3 readouts, balancing growth investments with cash runway into 2028.

Analyst consensus targets emphasize Monjuvi's contribution to €500M peak European sales by 2030.

Strategic independence post-acquisition rumors enhances focus on partnered assets like Monjuvi.

Competitive Landscape and Future Trials

Monjuvi competes with polatuzumab vedotin and CAR-Ts like axi-cel, but excels in outpatient administration and lower upfront costs.

Intepirdine and bispecific T-cell engagers represent next-gen threats, yet Monjuvi's established safety database provides a moat.

Phase 3 in follicular lymphoma, enrolling 450 patients, reads out in 2027, with endpoints including PFS superiority over rituximab.

Pediatric expansions and solid tumor explorations diversify beyond DLBCL, targeting orphan designations.

DACH sites lead recruitment in multi-center trials, underscoring regional expertise in lymphoma research.

Partnership dynamics with Incyte ensure global reach while retaining ex-US rights.

Manufacturing scale-up at Planegg facilities meets rising demand without supply disruptions.

Strategic Implications for DACH Healthcare

Monjuvi integrates into precision medicine pathways, with CD19 expression testing now routine in DACH pathology labs.

Training programs for hematologists emphasize combination sequencing, optimizing outcomes in resource-limited settings.

Economic models project €250M cumulative DACH sales by 2030, supporting R&D reinvestment.

Regulatory milestones, like pediatric investigation plans, extend exclusivity to 2036.

Sustainability efforts include recyclable packaging and carbon-neutral production, aligning with EU green deal priorities.

Patient advocacy partnerships enhance awareness, driving diagnosis rates in underserved rural areas.

Overall, Monjuvi exemplifies biotech's shift toward durable, accessible therapies for hematologic malignancies.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.